

Strategies and Activities	Short-term (Yrs 1-3) and Intermediate (Yrs 4-5) Outcomes	Long-term Outcomes
1. Core Viral Hepatitis Outbreak Response and Surveillance Activities		
<p>1.1 Develop, implement, and maintain plan to rapidly detect and respond to outbreaks of:</p> <p>Hepatitis A</p> <p>Hepatitis B</p> <p>Hepatitis C</p>	<p><i>Short-term Outcomes:</i></p> <p>Established jurisdictional framework for outbreak detection and response</p> <p>Earlier detection and response to viral hepatitis outbreaks</p> <p><i>Intermediate Outcomes:</i></p> <p>Reduced new cases of viral hepatitis</p>	<p>1. Establishment of comprehensive national viral hepatitis surveillance</p> <p>2. Reduced new viral hepatitis infections</p>
<p>1.2 Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for:</p> <p>Hepatitis A</p> <p>Acute hepatitis B</p> <p>Acute and chronic hepatitis C</p>	<p><i>Short-term Outcomes:</i></p> <p>Increased public health reporting of chronic and perinatal HCV and chronic HBV infection, and undetectable HCV RNA and HBV DNA laboratory results</p> <p>Improved monitoring of burden of disease and trends in hepatitis A, acute hepatitis B, and acute hepatitis C</p> <p>Improved monitoring of burden of disease and outcomes in chronic hepatitis C</p> <p><i>Intermediate Outcomes:</i></p> <p>Improved monitoring of hepatitis C continuum of cure (CoC)</p> <p>Improved development and utilization of viral hepatitis surveillance data reports</p>	<p>3. Increased access to care for persons with viral hepatitis</p> <p>4. Improved health outcomes for people with viral hepatitis</p> <p>5. Reduced deaths among people with viral hepatitis</p>
<p>1.3 Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for:</p> <p>Chronic hepatitis B</p> <p>Perinatal hepatitis C</p>	<p><i>Short-term Outcomes:</i></p> <p>Improved monitoring of burden of disease and trends in perinatal hepatitis C</p> <p><i>Intermediate Outcomes:</i></p> <p>Improved monitoring of burden of disease and outcomes in chronic hepatitis B</p> <p>Improved monitoring of hepatitis B CoC</p>	<p>6. Reduced viral hepatitis-related health disparities</p> <p>7. Decreased overdose deaths among PWID</p> <p>8. Decreased infections from drug use</p>
2. Core Viral Hepatitis Prevention Activities		
<p>2.1 Support viral hepatitis elimination planning and surveillance, and maximize access to testing, treatment, and prevention</p> <p>Increase routine HCV and HBV testing in high volume laboratories and health systems</p> <p>Expand provider capacity to treat hepatitis C and/or hepatitis B</p> <p>Disseminate materials regarding evidence-based</p>	<p><i>Short-term Outcomes:</i></p> <p>Increased state engagement with key stakeholders in viral hepatitis elimination planning</p> <p>Increased commercial and hospital-based laboratories conducting HCV RNA reflex testing</p> <p>Increased HCV and/or HBV testing in health care systems</p> <p><i>Intermediate Outcomes:</i></p> <p>Increased healthcare providers trained in prescribing hepatitis C and/or hepatitis B treatment</p> <p>Increased access to HCV treatment</p> <p>Increased access to SSPs for PWID</p>	

<p>best practices for access to HCV treatment and viral hepatitis prevention</p>		
<p>2.2 Increase access to HCV and HBV testing and referral to care in high-impact settings</p> <p>Increase routine HCV and HBV testing in high-impact settings</p> <p><i>Provide post-test counseling and referral to treatment or prevention</i></p>	<p><u>Short-term Outcomes:</u></p> <p>Increased access to HCV RNA reflex and/or HBV testing among persons receiving services in high-impact settings</p> <p>Increased awareness of infection status among people diagnosed with chronic hepatitis C and/or hepatitis B</p> <p>Increased referral to treatment for people living with hepatitis C and/or hepatitis B</p> <p>Increased referral to treatment and prevention services for persons who inject drugs (PWID)</p> <p><u>Intermediate Outcomes:</u></p> <p>Increased cure of hepatitis C</p>	
<p>2.3 Improve access to services preventing viral hepatitis and other bloodborne infections among PWID</p> <p><i>Support SSPs</i></p> <p><i>Establish hepatitis A and B vaccine delivery teams</i></p>	<p><u>Short-term Outcomes:</u></p> <p>Increased utilization of SSPs among PWID</p> <p>Increased referral of PWID to SUD treatment</p> <p>Increased receipt of hepatitis A and hepatitis B vaccination among clients in high-impact settings</p>	
<p>3. Special Projects: Prevention, Diagnosis, and Treatment related to the infectious disease consequences of drug use</p>		
<p>3.1 Improve access to services for PWID in settings disproportionately affected by drug use:</p> <p>Develop and implement PWID service bundle in settings that serve PWID (e.g., SSPs, MAT providers, hospital settings, correctional facilities)</p> <p>3.2 Implement prevention services and interventions to address emerging issues related to drug use</p> <p>Education and training to address emerging issues</p>	<p><u>Short-term Outcomes:</u></p> <p>Increased access to high-coverage needle-syringe exchange among PWID</p> <p>Increased linkage to SUD treatment (including MAT among PWID with OUD)</p> <p>Increased HCV, HIV, and HBV testing among PWID</p> <p>Increased linkage to treatment services among people with infectious complications (viral hepatitis, HIV, bacterial, fungal) of SUD</p> <p>Increased receipt of hepatitis B and A vaccination among PWID</p> <p>Increased dissemination of evidence-based interventions and guidance to reduce bacterial and fungal complications among PWID</p> <p><u>Intermediate Outcomes:</u></p> <p>Decreased new viral hepatitis, HIV and other infections (e.g., bacterial, fungal) among PWID</p> <p>Increased hepatitis C cures among PWID with hepatitis C</p> <p>Decreased unsafe injection practices</p>	